Sell-rated reports

287 tickers rated Sell
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Moderna, Inc.
MRNA·Healthcare
F Avoid
Current$254.19
Nov 9, 2026

Moderna's expanding mRNA vaccine portfolio and promising cancer immunotherapy pipeline could transform its earnings power, but persistent cash burn and an exceptionally demanding valuation leave little room for execution setbacks.

Score
35
Oklo Inc.
OKLO·Utilities
F Avoid
Current$23.55
Nov 9, 2026

Oklo offers exposure to rising demand for advanced nuclear electricity, supported by technical progress and substantial cash reserves, but unproven commercial reactor economics, heavy capital spending, and shareholder dilution make the investment highly speculative.

Score
34
Rigetti Computing, Inc.
RGTI·Technology
F Avoid
Current$10.33
Nov 13, 2026

Rigetti's modular superconducting quantum architecture and government-backed research create significant long-term growth potential, but weak commercialization, negative cash flow, dilution and demanding valuation undermine the investment case.

Score
30
D-Wave Quantum Inc.
QBTS·Technology
F Avoid
Current$9.84
Nov 13, 2026

D-Wave's commercial quantum computing platform and expanding contracted backlog offer substantial long-term growth potential, but extreme valuation, widening operating losses, and shareholder dilution undermine the current investment case.

Score
30
Lennar Corporation
Current$83.06
Sep 23, 2026

Lennar’s land-light model, buybacks, and U.S. housing undersupply offer recovery upside if affordability improves, but collapsing margins and weak orders leave earnings exposed if mortgage rates stay high.

Score
25
Kodiak Sciences Inc.
KOD·Healthcare
F Avoid
Current$41.36
Aug 17, 2026

Kodiak's validated biopolymer retina platform could transform the $12B anti-VEGF market, but an imminent cash cliff and going-concern warning favor staying sidelined until recapitalization.

Score
16
Regencell Bioscience Holdings Limited
RGC·Healthcare
F Avoid
Current$6.50
Nov 2, 2026

Regencell could unlock a specialized ADHD and autism treatment opportunity through successful TCM commercialization, but unproven clinical efficacy, zero product revenue, rising cash burn, and speculative valuation dominate the investment case.

Score
9
Li Auto Inc.
Current$12.23
Aug 30, 2026

Li Auto has a fortress balance sheet that secures its survival, but a broken growth engine, shrinking vehicle margins and an inability to defend its family SUV niche against Huawei make the stock a value trap in an oversupplied EV market.

Score
9